172 related articles for article (PubMed ID: 37366889)
21. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
22. Regulation of PGC-1α expression by a GSK-3β-TFEB signaling axis in skeletal muscle.
Theeuwes WF; Gosker HR; Schols AMWJ; Langen RCJ; Remels AHV
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118610. PubMed ID: 31738957
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells.
Li Z; Tan F; Thiele CJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3113-21. PubMed ID: 18089706
[TBL] [Abstract][Full Text] [Related]
24. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells.
Ougolkov AV; Fernandez-Zapico ME; Savoy DN; Urrutia RA; Billadeau DD
Cancer Res; 2005 Mar; 65(6):2076-81. PubMed ID: 15781615
[TBL] [Abstract][Full Text] [Related]
25. The effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance.
Liang CQ; Fu YM; Liu ZY; Xing BR; Jin Y; Huang JL
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):5008-5016. PubMed ID: 29164556
[TBL] [Abstract][Full Text] [Related]
26. GSK-3β inhibition by curcumin mitigates amyloidogenesis via TFEB activation and anti-oxidative activity in human neuroblastoma cells.
Song HC; Chen Y; Chen Y; Park J; Zheng M; Surh YJ; Kim UH; Park JW; Yu R; Chung HT; Joe Y
Free Radic Res; 2020 Dec; 54(11-12):918-930. PubMed ID: 32623920
[TBL] [Abstract][Full Text] [Related]
27. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
28. Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells.
Zhang ZY; Dong SM; Liu YH; Zhang MM; Zhang JK; Zhu HJ; Shao JA; Liu HQ; Li YL; Zhang C; Zeng LH
Anticancer Drugs; 2021 Aug; 32(7):727-733. PubMed ID: 33735117
[TBL] [Abstract][Full Text] [Related]
29. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
31. Signal transducers and activators of transcription 3-induced metastatic potential in gastric cancer cells is enhanced by glycogen synthase kinase-3β.
Yoon J; Ko YS; Cho SJ; Park J; Choi YS; Choi Y; Pyo JS; Ye SK; Youn HD; Lee JS; Chang MS; Kim MA; Lee BL
APMIS; 2015 May; 123(5):373-82. PubMed ID: 25846563
[TBL] [Abstract][Full Text] [Related]
32. BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.
Li F; Yang C; Zhang HB; Ma J; Jia J; Tang X; Zeng J; Chong T; Wang X; He D; Guo P
Cancer Med; 2019 Aug; 8(10):4792-4805. PubMed ID: 31250978
[TBL] [Abstract][Full Text] [Related]
33. GSK-3β inhibition elicits a neuroprotection by restoring lysosomal dysfunction in neurons via facilitation of TFEB nuclear translocation after ischemic stroke.
Zhang Y; Wu Z; Huang Z; Liu Y; Chen X; Zhao X; He H; Deng Y
Brain Res; 2022 Mar; 1778():147768. PubMed ID: 34968440
[TBL] [Abstract][Full Text] [Related]
34. Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas.
Atkins RJ; Dimou J; Paradiso L; Morokoff AP; Kaye AH; Drummond KJ; Hovens CM
J Clin Neurosci; 2012 Nov; 19(11):1558-63. PubMed ID: 22999562
[TBL] [Abstract][Full Text] [Related]
35. Novel anti-inflammatory role for glycogen synthase kinase-3beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1beta-induced inflammatory gene expression.
Vines A; Cahoon S; Goldberg I; Saxena U; Pillarisetti S
J Biol Chem; 2006 Jun; 281(25):16985-16990. PubMed ID: 16601113
[TBL] [Abstract][Full Text] [Related]
36. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth.
Kroon J; in 't Veld LS; Buijs JT; Cheung H; van der Horst G; van der Pluijm G
Oncotarget; 2014 Oct; 5(19):8986-94. PubMed ID: 25344861
[TBL] [Abstract][Full Text] [Related]
37. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
Ban JO; Kwak DH; Oh JH; Park EJ; Cho MC; Song HS; Song MJ; Han SB; Moon DC; Kang KW; Hong JT
Chem Biol Interact; 2010 Oct; 188(1):75-85. PubMed ID: 20540935
[TBL] [Abstract][Full Text] [Related]
38. GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death.
Yang J; Takahashi Y; Cheng E; Liu J; Terranova PF; Zhao B; Thrasher JB; Wang HG; Li B
J Cell Sci; 2010 Mar; 123(Pt 6):861-70. PubMed ID: 20159967
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of GSK-3β alleviates cerebral ischemia/reperfusion injury in rats by suppressing NLRP3 inflammasome activation through autophagy.
Wang Y; Meng C; Zhang J; Wu J; Zhao J
Int Immunopharmacol; 2019 Mar; 68():234-241. PubMed ID: 30703695
[TBL] [Abstract][Full Text] [Related]
40. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.
Yu AS; Zhao L
Tumour Biol; 2016 Apr; 37(4):4857-64. PubMed ID: 26526575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
